

**Lisa Ramos**

---

**From:** EDWARD TREISMAN <ejtmd@att.net>  
**Sent:** Sunday, October 27, 2019 7:50 PM  
**To:** Lisa Ramos  
**Subject:** Distinguished Alumni Award  
**Attachments:** JT distinguished Nomination.docx

Dear Lisa,  
Following is a submission for the Distinguished Alumni Award:

October 25, 2019

Lisa Ramos,  
Mgr, SOM Alumni Affairs  
540 E. Canfield  
1369 Scott Hall  
Detroit, 48201

Re: Distinguished Alumni Award

Dear Ms. Ramos:

It gives me great pleasure to nominate Jonathan S. Treisman M.D. for the Distinguished Alumni Award.

Jonathan Treisman has worked at the cutting edge of cancer medicine since he was an undergraduate student. He studied novel anti-cancer agents as a chemist, then studied bone marrow transplants as a cutting edge anti-cancer treatment, and finally did

pioneering work in immunotherapy with chimeric T-cells at the NIH. He has spent the last 25 years as a leading oncologist in Milwaukee where he has been an exemplary clinician scientist by providing remarkable clinical care of his patients, continuing an academic career and producing scholarship, new knowledge and numerous publications.

Dr. Treisman began his career as a chemist working on anti-cancer drugs at Wayne State in the laboratory of Jerome Horwitz (discoverer of AZT) as a summer student. He graduated from Wayne State University Medical School class of 1984 with an ongoing interest in cancer medicine and then completed a residency in Internal Medicine at the University of Michigan before moving to the Fred Hutchinson Research Cancer center in Seattle where he did his fellowship in Hematology-Oncology with a specialization in bone marrow transplantation.

In 1990 he began working at the NIH in the laboratory of Steve Rosenberg where he did research in then emerging field of cancer immunotherapy and conducted basic research on the chimeric T-cell receptor. During that time he was sent as a Visiting Research associate to the Weizmann Institute in Israel.

After five years at the NIH he moved on to Milwaukee serving as Section Chief of Oncology at Aurora St. Luke's hospital and as the St. Luke's Immunotherapy Lab liaison. He became Medical Director of Wheaton Franciscan Cancer Center in Milwaukee, Wisconsin.

He is currently both the Medical director of Oncology and Director of Oncology Research at the Ascension Health System in Wisconsin.

Jonathan's wife Ruth is a Nurse Practitioner and Professor of Nursing at the University of Wisconsin. Their son is a PhD Neurobiologist in DC. One of their two daughters is completing a PhD in Nursing while the other is pursuing an academic career.

Dr. Treisman's career in oncology, immunology, research and health care gives great credit to his basic education and training at Wayne State University Medical School.

Attached is a copy of Dr. Jonathan Scott Treisman's CV.

Respectfully submitted,

Edward J. Treisman MD  
WSU Class of 1954

## **Curriculum Vitae – Jonathan Treisman, M.D.**

**Name** Jonathan Scott Treisman, M.D.

**Home** 2701 East Beverly Road Shorewood, WI  
53211

**Born** October 15, 1958, Detroit, Michigan

**Family** Married, three children

**Citizenship** United States

### **CURRENT TITLE**

Clinical Assistant Professor, Medical College of  
Wisconsin.

Junior PI, CROWN Consortium

### **OFFICE ADDRESS**

Wheaton Franciscan Healthcare

Reiman Center for Cancer Care

7410 West Rawson Avenue

Franklin, WI 53132

### **EDUCATION**

1980 B.S. with honors in chemistry, University of  
Michigan, Ann Arbor, MI

1984 M.D., Wayne State University, School of  
Medicine, Detroit, MI

## **POST GRADUATE TRAINING**

1984-1985 Internship in Internal Medicine, University  
of Michigan, Ann Arbor, MI

1985-1987 Residency in Internal Medicine, University  
of Michigan, Ann Arbor, MI

1987-1990 Fellowship in Medical Oncology, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA

1990 Visiting Scientist, Weizmann Institute, Rehovot, Israel

1991-1995 Senior Staff Fellow, National Cancer Institute, National Institutes of Health, Bethesda, MD

## **CLINICAL POSITIONS**

1985-1987 Emergency Room Staff, Beyer Memorial Hospital, Ypsilanti, MI

1987-1990 Medical Staff, Group Health Cooperative, Seattle, WA

1987-1990 Medical Staff, Hall Health Clinic, University of Washington, Seattle, WA

1995-2011 Hartford Memorial Hospital, Hartford, WI

1995-2010 Section Chief, Oncology, Aurora St. Luke's Medical Center, Milwaukee, WI

1995-2010 St. Francis Hospital, Milwaukee, WI



1995-2010 Sinai-Samaritan Medical Center,  
Milwaukee, WI

1995-2011 Clinical Assistant Professor, University of  
Wisconsin, Madison, WI

2010-2011 Managing Partner, Medical Consultants,  
Milwaukee, WI

2010- 2018 Medical Director, Wheaton Franciscan  
Cancer Care, Milwaukee, WI

2014- Clinical Assistant Professor, Medical College of  
Wisconsin, Milwaukee, WI

2018 – Member, Ascension Wisconsin Research  
Institute, Milwaukee, WI

2019 - Junior PI, CROWN Consortium (Cancer  
Research of Wisconsin & Northern Michigan)

## **AWARDS**

1978 Summer Fellowship, Michigan Cancer  
Foundation, Detroit, MI

1980 Gomberg Research Fellowship, University of  
Michigan, Department of Chemistry

1981 Summer Fellowship, Wayne State University,

Detroit, MI

1987 Senior Research Fellowship, University of Michigan, Ann Arbor, MI

National Research Training Award, CA 09515, University of Washington, Seattle, WA

1989 UpJohn Travel Award, University of Washington, Seattle, WA

1990 Visiting Scientist, Weizmann, Institute of Science, Rehovot, Israel

2010 Fellow of the American College of Physicians

2019 Innovator Award, Association of Community Cancer Centers

## **RESEARCH AND TEACHING POSITIONS**

1978-1980 Research Assistant, Department of Chemistry, University of Michigan, Ann Arbor, MI

1983-1984 Surgical Assistant, Mt. Carmel Mercy Hospital, Detroit, MI

1987 Lecturer, Department of Pharmacology, University of Michigan, Ann Arbor, MI

1993 Guest Lecturer, BIO-TRAC, Foundation for Advanced Education in the Sciences, Bethesda, MD

1996 Adult Medical Teaching Service, Aurora St.

Luke's Medical Center, Milwaukee, WI

1996 Hematology/Oncology Service, Aurora Sinai  
Hospital, Milwaukee, WI

## **LICENSURE AND BOARD CERTIFICATION**

1984 State of Michigan (inactive)

1987 State of Washington (inactive)

1987 American Board of Internal Medicine

1989 ABIM Specialist Boards in Medical Oncology

1994 State of Maryland

1995 State of Wisconsin

2014 ABIM Specialist Board in Hematology

## **HOSPITAL AFFILIATIONS**

Wheaton Franciscan Healthcare – St. Joseph's  
Hospital, Milwaukee WI

Wheaton Franciscan Healthcare – St. Francis  
Hospital, Milwaukee WI

Wheaton Franciscan Healthcare – Franklin Hospital,  
Franklin WI

Aurora St. Luke's Medical Center, Milwaukee WI

Select Specialty Hospital, West Allis WI

Froedtert Hospital, Milwaukee WI

West Allis Memorial Hospital, West Allis, WI

## **MEMBERSHIPS/COMMITTEES**

American Medical Association

Wisconsin State Medical Society

American College of Physicians

Society of Biologic Therapy

1995-1998 Medical Director, VNA Hospice

1995-2010 Cancer Committee, Aurora St. Luke's Medical Center

1995-2013 Member, Autologous Stem Cell Transplant Service

1995- Member, Immunotherapy Service

1997-1998 Pharmacy & Therapeutics Committee, Aurora St. Luke's Medical Center

1997-2010 Organ Transplant Advisory Committee, Aurora St. Luke's Medical Center

1999-2010 Investigational Review Board

2003 Kidney Cancer Association Speaker

2011- Cancer Committee, Wheaton Franciscan Healthcare

2014 Prometheus Advisory Board

2014-2016 Prometheus Speaker

2015 BMS Advisory Board

2016 ICLIO Emerging Tumors Subcommittee

2016-present ECOG Senior Investigator, Wheaton  
Franciscan Healthcare

## BIBLIOGRAPHY

1. Horwitz JP, Brukwinski W, **Treisman J**, Andrzejewski D, Hills EB, Chung HL, Wang CY. Ethchlorvynol: Potential of metabolites for adverse effects in man. *Drug Met. & Dispos.*, 8: 77-83, 1980.
2. **Treisman J**, Collins FS. Adult Turner Syndrome associated with chylous ascites and vascular anomalies. *Clinical Genetics*, 31: 218-223, 1987.
3. **Treisman J**, Higuchi CM, Thompson JA, Gillis S, Lindgren C, Kern D and Fefer A. Interleukin-4 enhances the proliferation of lymphocytes from IL-2-treated cancer patients induced by IL-2 or mitogenic antibodies. *Cancer Res.*, 50: 110-1164, 1990.
4. Fox DA, Millard JA, **Treisman J**, Zeldes W, Bergman A, Depper J. and McCune WJ. Defective CD2 pathway T-cell activation in systemic lupus erythematosus. *Arthritis Rheum.*, 34, 561-571, 1991.
5. Eshhar Z, Gross G., **Treisman J**. Modifying the specificity of T-cells using chimeric Ig/TCR genes in *Practical Approach to Tumor Immunology*. G. Gallagher, Ed., IRL Books, Oxford, 1992.
6. Hwu P, Shafer G, **Treisman J**, Schindler DG, Gross G, Cowherd G, Rosenberg SA and Eshhar Z. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fe receptor g chain.

- J. Exp. Med., 178: 361-366, 1993.
7. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, **Treisman J**, Rosenberg, S.A. Expression of the MAGE-1 is upregulated by the demethylating agent 5-aza 2-deoxycytidine. *Cancer Res.*, 54, 1766-1771, 1994.
  8. **Treisman J**, Hwu P, Yanelli JR, Shafer GE, Cowherd R, Samid D, and Rosenberg, SA. Upregulation of tumor necrosis factor alpha production by retrovirally-transduced tumor infiltrating lymphocytes using trans-retinoic acid. *Cellular Immunol.*, 156, 448-457, 1994.
  9. **Treisman J**, Hwu P, Minamoto S, Shafer GE, Cowherd R, Morgan RA and Rosenberg, S.A. Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. *Blood* 85, 139-145, 1995.
  10. Hwu P, Yang JC, Cowherd R, **Treisman J**, Eshhar Z and Rosenberg, SA. In vivo anti-tumor activity of T-cells redirected with chimeric antibody/T-cell receptor genes. *Cancer Res.* 55, 3369-73, 1995.
  11. Minamoto S, **Treisman J**, Hankins WD, Sugamura K, Rosenberg SA. Acquired erythropoietin responsiveness of Interleukin-2-dependent T-lymphocytes transduced with genes encoding chimeric erythropoietin/Interleukin-2 receptors. *Blood* 86, 2281-2287, 1995.



12. Minamoto T, Royal RE, Kershaw MH, **Treisman J**, Wang G, Li W, Herlyn D, Eshhar Z, Hwu P. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. *Cancer Gene Ther.* 2000 Feb;7(2):284-91.
13. Lum LG, LeFever AV, **Treisman JS**, Garlie NK, Hanson JP: Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells –phase I clinical trial. *J Immunother.* 24:408-419, 2001.
14. Royal RE, Kershaw MH, Reeves ME, Wang G, Daly T, **Treisman J**, Lam J, Hwu P. Increased functional expression of transgene in primary human lymphocytes using retroviral vectors modified with IRES and splicing motifs. *Gene Ther.* 9, 1085-92, 2002.
15. Chinnasamy D, Fairbairn LJ, Neuenfeldt J, **Treisman JS**, Hanson JP Jr, Margison GP, Chinnasamy N. Lentivirus-mediated expression of mutant MGMP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide. *Hum Gene Ther.* 15, 758-69, 2004.
16. Chinnasamy N, **Treisman JS**, Oaks MS, Hanson JP, Chinnasamy D. Ex vivo generation of genetically modified dendritic cells for immunotherapy; implications of lymphocyte contamination. *Gene Ther.* 12:259-71, 2005.

17. **Treisman J**, Garlie N. Systemic Therapy for Cutaneous Melanoma. *Clin Plast Surg*. 2010 Jan;37(1):127-46. Review.
18. Schwartzenruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, **Treisman J**, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. *N Engl J Med*. 2011 Jun 2;364(22):2119-27. doi: 10.1056/NEJMoa1012863.
19. Brinkerhoff BT, Choong NW, **Treisman JS**, Poetker DM. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia. *Am J Otolaryngol*. 2012 May-Jun;33(3):349-51. doi: 10.1016/j.amjoto.2011.07.012. Epub 2011 Sep 13.
20. Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, Lemoli RM, Rao K, Maris M, Pagliuca A, Uberti J, Scheid C, Noppeney R, Cook G, Bokhari SW, Worel N, Mikala G, Masszi T, Taylor R, **Treisman J**. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. *Bone Marrow Transplant*. 2012 Jan;47(1):18-23. doi: 10.1038/bmt.2011.9. Epub 2011

Feb 28.

21. Richards JO, **Treisman J**, Garlie N, Hanson JP, Oaks MK. Flow cytometry assessment of residual melanoma cells in tumor-infiltrating lymphocyte cultures. *Cytometry A*. 2012 May;81(5):374-81. doi: 10.1002/cyto.a.22047. Epub 2012 Mar 29.
22. Wang J, Udd KA, Vidisheva A, Swift RA, Spektor TM, Bravin E, Ibrahim E, **Treisman J**, Masri M, Bereson JR. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with sever neuropathy. *Support Cancer Care*. 2016 Jul;24(7) 3105-10.doi10.1007/s00520-016-3126-1.
23. Clark JI, Wong MK, Kaufman HI, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Radraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Asim A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, **Treisman JS**, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S . Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients with Metastatic Renal Cell Carcinoma From and ON-going Observation IL-2 Clinical Trial: PROCLAIM. 2017 Feb, 15 (1):31-41e. doi, org/10.1016/j.clgc.2016.10.008

## ABSTRACTS

1. Treisman, J. and Koreeda, M. Synthesis of naturally occurring high-energy brominated epoxides. Honors chemistry research thesis. University of Michigan Department of Chemistry, 1980.
2. Treisman, J. and Fox, D. Abnormal T-cell activation by the alternative pathway in systemic lupus erythematosus. Senior Resident Research Conference, University of Michigan, 1987.
3. Treisman, J., Kern, D., Thompson, J.A., Higuchi, C., Gillis, S., Lindgren, C., Martin, P. and Fefer, A. Interleukin-4 augments the proliferative response of human lymphocytes to anti-CD3 and anti-CD28 after activation by Interleukin-2. Proc. Amer. Assoc. Canc. Res. Abstract #1282, 1989.
4. Treisman, J., Higuchi, C.M., Thompson, J.A., Lindgren, C. and Fefer, A. Anti-CD3 and anti-CD28 augment in vitro expansion of lymphocytes infiltrating human renal cell tumors. Proc. Amer. Assoc. Canc. Res. Abstract #1649, 1990.
5. Higuchi, C.M., Treisman, J., Thompson, J.A., Lindgren, C and Fefer, A. Cytolytic T-lymphocytes infiltrating human melanoma expanded by culture and Interleukin-2. Proc. Amer. Assoc. Canc. Res. Abstract #3816, 1990.
6. Thompson, J.A., Collins, C., Higuchi, C., Treisman,

J., Benz, L., Lindgren, C., Levitt, D. and Fefer, A. High-dose continuous intravenous infusion Interleukin-2 and lymphokine-activated killer cell therapy for renal cell carcinoma. Proc. Amer. Assoc. Canc. Res. Abstract #5614.

7. Treisman, J., Gross, G., Waks, T., Shafer, G., Rosenberg, S.A. and Eshhar, Z. Expression of chimeric immunoglobulin T-cell receptors with anti-tumor specificity. Proc. Amer. Assoc. Canc. Res. 1991.

8. Rohloff C, Garlie N, Hanson JP Jr, Treisman JS, LeFever A: Interleukin-12-primed activated T cells given with 5FU, GM-CSF and interferon alpha-2B for patients with renal cell (RCC) or colorectal cancer. 2nd Int Kidney Cancer Symp, Chicago, IL, Oct 25-27, 2001.

9. Rohloff C, Garlie N, Hanson JP Jr, Treisman JS, LeFever A: Interleukin-12-primed activated T cells given with 5FU, GM-CSF and interferon alpha-2B for patients with renal cell (RCC) or colorectal carcinoma. 93rd Ann Mtg Am Assoc Cancer Res, San Francisco, Apr 6-10, 2002.

10. LeFever AV, Rohloff C, Treisman JS, Hanson JP Jr, Garlie NK: Adoptive immunotherapy with Interleukin-12-primed activated T cells in patients with renal cell (RCC) or colorectal carcinoma (CRC). ASCO Proc, 22:181, 2003.

11. Treisman JS, Morris R, Garlie N, LeFever A, Hanson JP Adjuvant activated T-cell (ATC) therapy for patients with non-metastatic or resected metastatic renal cell carcinoma. J Clin Oncol 26: 2008 (May 20 suppl; abstr 5041)

